Tokyo, Jan. 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060360) titled 'Effects of consumption of the test food on the shoulder joint' on Jan. 15.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - ICHIMARU PHARCOS Co., Ltd.

Condition: Condition - Healthy Japanese Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To conduct exploratory verification of the effects of consumption of the test food on the shoulder joint Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Duration: 12 weeks The test food Interventions/Control_2 - Duration: 12 weeks Placebo

Eligibility: Age-lower limit - 40 years-old =60 points) at Scr Key exclusion criteria - 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction

2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"

5. Individuals who are taking or using medications (including herbal medicines) and supplements

6. Individuals who are allergic to medicines and foods related to the test product, particularly those who are allergic to salmon or gelatin

7. Individuals who are pregnant, lactating, or planning to become pregnant during this study

8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study

9. Individuals who usually use (e.g., glucosamine hydrochloride, chondroitin, collagen peptide, hyaluronic acid, or DHA / EPA) that affect the joint

10. Individuals who plan to start exercise that put intense stress on the joint

11. Individuals who are judged as ineligible to participate in this study by the physician Target Size - 20

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2025 Year 12 Month 10 Day Date of IRB - 2025 Year 12 Month 10 Day Anticipated trial start date - 2026 Year 01 Month 15 Day Last follow-up date - 2026 Year 06 Month 25 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069055

Disclaimer: Curated by HT Syndication.